针对大脑的勒-黑色素皮质通路治疗心力衰竭
Ana C M Omoto1, Jussara M do Carmo2, Alan J Mouton2
1Department of Physiology and Biophysics, Cardiorenal and Metabolic Diseases Research Center, Mississippi Center for Obesity Research, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, USA. aomoto@umc.edu.
Current hypertension reports
|November 29, 2024
概括
中枢神经系统丁受体激活改善心脏代谢和功能,提供对心力衰竭和心肌梗塞的保护. 这条大脑-心脏通路有可能成为新的治疗策略.
科学领域:
- 心血管生理学心血管生理学
- 神经内分泌学神经内分泌学
- 代谢调节 代谢调节 代谢调节 代谢调节
背景情况:
- 由于研究结果相互矛盾,勒普丁在心脏功能中的作用受到争议.
- 以前的研究往往忽略了叶黄素对心脏的中枢神经系统 (CNS) 影响.
- 素对心脏的益处可能源于其对中枢神经系统素受体 (LepRs) 和下游通路的作用.
研究的目的:
- 通过中枢神经系统 (CNS LepRs) 审查素在心脏调节中的作用.
- 探索下游的信号传输,包括大脑的黑色素皮质蛋白系统.
- 要突出中枢神经系统 LepR 激活对心脏代谢和功能的影响.
主要方法:
- 关于瘦素和心脏功能的临床前和临床研究的综述.
- 专注于研究中枢神经系统瘦素受体激活的研究.
- 对大脑黑色素皮质蛋白系统参与的分析.
主要成果:
- 中枢神经系统的LepR激活,独立于血瘦素水平,显著改善心脏代谢和功能.
- 这些效应可以防止心力衰竭 (HF) 和心肌梗塞 (MI).
- 心脏保护是由大脑中的普罗皮欧梅拉诺科廷 (POMC) 神经元和梅拉诺科廷4受体 (MC4R) 介导的.
结论:
- 长期激活大脑丁-黑色皮质素通路,可以改善心脏功能和MI后的新陈代谢.
- 这种脑心交叉通话的精确机制需要进一步阐明.
- 了解这种途径可能会导致MI和HF的新型治疗方法.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
386
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386
Heart Failure Drugs: β-Blockers
316
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316
Heart Failure Drugs: Diuretics
343
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
343
Regulation of Food Intake
193
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
193
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K


